Subsequent events |
12 Months Ended |
|---|---|
Dec. 31, 2025 | |
| Subsequent events | |
| Subsequent events | 16. Subsequent events In March 2026, the Company announced the strategic reprioritization of its clinical portfolio to focus on its promising pipeline of next-generation therapeutics, including nuzefatide pevedotin as well as next-generation Bicycle conjugates, including BRC molecules. In conjunction with its strategic reprioritization, the Company is implementing a proposed workforce reduction of approximately 30% of its workforce. Together, the workforce reduction and strategic reprioritization are expected to reduce the Company’s annual operating expenses by approximately 50% based on the Company’s current plans. The Company expects the workforce reduction to be substantially completed by the end of 2026 and to recognize aggregate charges for severance and other employee termination benefits of approximately $8.0 million.
|